XML 52 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Discontinued Operations and Equity-Method Investment - Summarized Financial Information of Discontinued Operations (Details) - USD ($)
$ in Millions
 3 Months Ended
Apr. 04, 2021
Mar. 29, 2020
Costs and expenses:    
Income from discontinued operations––net of tax $ 9 $ 881
Discontinued Operations [Member]    
Income Statement Disclosures    
Revenues [1] 27 1,946
Costs and expenses:    
Cost of sales [1] 14 442
Selling, informational and administrative expenses [1] (8) 332
Research and development expenses [1] 1 51
Amortization of intangible assets [1] 0 36
Restructuring charges and certain acquisition-related costs [1] 0 15
Other (income)/deductions––net [1] 1 70
Pre-tax income from discontinued operations [1] 19 1,000
Provision for taxes on income [1] 10 119
Income from discontinued operations––net of tax [1] $ 9 $ 881
[1] In the three months ended April 4, 2021, Income from discontinued operations—net of tax primarily relates to the Mylan-Japan collaboration, which did not terminate until December 21, 2020 and which falls in Pfizer’s international first quarter of 2021, and adjustments to tax and legal matters directly related to the disposed Upjohn Business. In the three months ended March 29, 2020, Income from discontinued operations—net of tax relates to the Upjohn Business and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting, which has been applied on a retrospective basis for all prior periods presented. See Note 1C.